ARTERIOCYTE MEDICAL SYSTEMS, INC.
HOPKINTON, MA

ST. LOUIS (OCT. 19, 2016) – Isto Holdings, the parent company of St. Louis-based Isto Technologies – a leader in bone-regeneration technologies and cell-based therapy – has acquired medical-device company Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, with plans to integrate the companies under the name Isto Biologics. Isto Biologics will be focused on offering evidence-based solutions to expand its spine, orthopedics, and functional-medicine product portfolios. Isto Biologics will be headquartered in St. Louis, while maintaining operations in Massachusetts. “We’re excited to bring together two great organizations under the Isto umbrella and build upon their leading biologics platforms,” said Anthony Chambers, Director at Thompson Street Capital Partners, which provided capital for the transaction. “Both Isto and Arteriocyte have achieved remarkable success by developing innovative, clinically-proven product offerings that help improve patient outcomes. The integrated product portfolio, combined with the expanded sales force and broader distribution network, will allow Isto Biologics to extend its reach within the spine, orthopedics, and functional-medicine markets.” George Dunbar, current CEO of Isto Technologies, will serve as CEO of Isto Biologics. “We are grateful for the support of Thompson Street Capital Partners and excited to lead Isto Biologics into the future,” said Mr. Dunbar. “The integration of Isto and Arteriocyte presents an opportunity to leverage our combined expertise to establish a strong position in an ever-changing market and better serve our physician partners, as they work to grow their practice and meet the demands of value-based healthcare.” Isto Biologics’ expanded, best-in-class product portfolio will feature Arteriocyte’s market-leading MAGELLAN Autologous Platelet Separator and Isto’s bone growth and cell-therapy products, including InQu Arteriocyte Medical Systems, Inc. is a leading medical device company committed to developing and marketing novel medical products to help patients heal faster. Established in 2007 by Arteriocyte, Inc. and DW Healthcare Partners, Arteriocyte Medical Systems is devoted to providing innovative solutions to patients and medical professionals to address serious unmet medical needs particularly in cardiac, orthopedic and vascular surgeries. will expand best-in-class product portfolios and build upon their deep scientific expertise in biologics and cell therapy to provide better patient outcomes.